Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACER: Cetuximab plus image-guided radiotherapy in locally advanced pancreatic cancer
2006-001742-13Phase 2Terminated
- Sponsor
- The Christie
- Start
- Sep 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in pancreatic adenocarcinoma (PDAC), sponsored by The Christie. Primary endpoint: Progression-free survival rate. Started Sep 2006; status: terminated.
02
Drugs
cetuximab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2006-001742-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001742-13.